308 related articles for article (PubMed ID: 26586670)
1. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.
Sutherland A; Forsyth A; Cong Y; Grant L; Juan TH; Lee JK; Klimowicz A; Petrillo SK; Hu J; Chan A; Boutillon F; Goffin V; Egan C; Tang PA; Cai L; Morris D; Magliocco A; Shemanko CS
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26586670
[TBL] [Abstract][Full Text] [Related]
2. What Is Breast in the Bone?
Shemanko CS; Cong Y; Forsyth A
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27782069
[TBL] [Abstract][Full Text] [Related]
3. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
5. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
[TBL] [Abstract][Full Text] [Related]
6. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
7. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
8. Expression of prolactin and its receptor in human breast carcinoma.
Reynolds C; Montone KT; Powell CM; Tomaszewski JE; Clevenger CV
Endocrinology; 1997 Dec; 138(12):5555-60. PubMed ID: 9389544
[TBL] [Abstract][Full Text] [Related]
9. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
10. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
11. Prolactin receptor in breast cancer: marker for metastatic risk.
Shemanko CS
J Mol Endocrinol; 2016 Nov; 57(4):R153-R165. PubMed ID: 27658959
[TBL] [Abstract][Full Text] [Related]
12. Alpha
Castillo LF; Rivero EM; Goffin V; Lüthy IA
Cell Signal; 2017 Jun; 34():76-85. PubMed ID: 28302567
[TBL] [Abstract][Full Text] [Related]
13. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
14. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
15. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
Standing D; Dandawate P; Anant S
Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
[TBL] [Abstract][Full Text] [Related]
16. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
17. Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy.
López-Ozuna VM; Hachim IY; Hachim MY; Lebrun JJ; Ali S
Sci Rep; 2016 Aug; 6():30934. PubMed ID: 27480353
[TBL] [Abstract][Full Text] [Related]
18. A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration.
Li R; Yang Y; Lan H; Wang Y; Ge Z; Liu X; Zhou Y; Zhang W; Xian L; Yuan H
Endocrinology; 2023 Nov; 164(12):. PubMed ID: 37934803
[TBL] [Abstract][Full Text] [Related]
19. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
[TBL] [Abstract][Full Text] [Related]
20. Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
Plotnikov A; Varghese B; Tran TH; Liu C; Rui H; Fuchs SY
Cancer Res; 2009 Apr; 69(7):3165-72. PubMed ID: 19276348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
